Sachi Bio

Sachi Bio is an RNA therapeutic platform company with a lead autoimmune (inflammasome inhibitor) program that has shown rapid remission and relief in aggressive Ulcerative Colitis and Multiple Sclerosis models (>90% reduction in inflammation in <1week), with excellent target product (oral, shelf-stable, long half-life) and safety-biodistribution profile.

Sachi Bio’s platform performs target identification, and first-in-class lead generation, with high-throughput and precision, great safety profile, both gain-of-function and loss-of-function, multiple routes of administration (oral, inhalable, injectable, infusion) and high-bioavailability.